The NovoTTF-100A System uses electrodes to treat glioblastoma multiforme (GBM), the most aggressive form of brain tumor.
In 2010, there were 13,140 deaths from brain and other nervous system cancers in the United States. In April 2011, the FDA approved the NovoTTF-100A System that will offer new hope for adults with recurring or progressing GBM even after receiving chemotherapy and radiation therapies.
In 2010, there were 13,140 deaths from brain and other nervous system cancers in the United States. In April 2011, the FDA approved the NovoTTF-100A System that will offer new hope for adults with recurring or progressing GBM even after receiving chemotherapy and radiation therapies.